$AMRN
AMARIN CORP PLC\UK

2018 Q2 Form 10-Q Financial Statement

#000156459018018242 Filed on August 01, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $52.64M $45.24M
YoY Change 16.36% 36.63%
Cost Of Revenue $12.85M $11.40M
YoY Change 12.67% 28.66%
Gross Profit $39.80M $33.84M
YoY Change 17.6% 39.55%
Gross Profit Margin 75.6% 74.8%
Selling, General & Admin $53.90M $31.50M
YoY Change 71.11% 20.85%
% of Gross Profit 135.44% 93.09%
Research & Development $18.20M $13.70M
YoY Change 32.85% 8.92%
% of Gross Profit 45.73% 40.48%
Depreciation & Amortization $160.0K $180.0K
YoY Change -11.11% -10.0%
% of Gross Profit 0.4% 0.53%
Operating Expenses $72.10M $45.24M
YoY Change 59.38% 17.07%
Operating Profit -$32.31M -$11.40M
YoY Change 183.41% -20.81%
Interest Expense -$1.773M -$2.315M
YoY Change -23.41% -58.78%
% of Operating Profit
Other Income/Expense, Net -$100.0K $80.00K
YoY Change -225.0% -143.96%
Pretax Income -$34.20M -$13.63M
YoY Change 150.84% -5.2%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$34.21M -$13.63M
YoY Change 150.92% 2.1%
Net Earnings / Revenue -64.98% -30.14%
Basic Earnings Per Share -$0.12 -$0.05
Diluted Earnings Per Share -$0.12 -$0.05
COMMON SHARES
Basic Shares Outstanding 293.7M 270.7M
Diluted Shares Outstanding 293.7M 270.7M

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $102.3M $85.50M
YoY Change 19.65% 17.93%
Cash & Equivalents $102.9M $85.46M
Short-Term Investments
Other Short-Term Assets $3.500M $2.700M
YoY Change 29.63% -55.74%
Inventory $40.10M $24.81M
Prepaid Expenses
Receivables $50.30M $37.48M
Other Receivables $0.00 $0.00
Total Short-Term Assets $196.1M $150.4M
YoY Change 30.36% 29.11%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $52.00K
YoY Change -100.0% -62.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $173.0K
YoY Change 15.61% -0.57%
Total Long-Term Assets $8.000M $19.76M
YoY Change -59.51% -36.52%
TOTAL ASSETS
Total Short-Term Assets $196.1M $150.4M
Total Long-Term Assets $8.000M $19.76M
Total Assets $204.1M $170.2M
YoY Change 19.93% 15.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.50M $16.46M
YoY Change 109.66% 11.1%
Accrued Expenses $73.80M $49.10M
YoY Change 50.31% 57.88%
Deferred Revenue $1.056M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $28.40M $18.83M
YoY Change 50.8% -38.89%
Total Short-Term Liabilities $137.6M $86.29M
YoY Change 59.46% 10.84%
LONG-TERM LIABILITIES
Long-Term Debt $88.70M $79.28M
YoY Change 11.88% -12.05%
Other Long-Term Liabilities $24.50M $1.158M
YoY Change 2015.72% 332.09%
Total Long-Term Liabilities $113.2M $80.44M
YoY Change 40.72% -11.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $137.6M $86.29M
Total Long-Term Liabilities $113.2M $80.44M
Total Liabilities $250.8M $208.9M
YoY Change 20.03% -33.04%
SHAREHOLDERS EQUITY
Retained Earnings -$1.239B
YoY Change 6.7%
Common Stock $1.179B
YoY Change 21.18%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.902M
YoY Change 225.98%
Treasury Stock Shares $1.610M
Shareholders Equity -$46.69M -$38.76M
YoY Change
Total Liabilities & Shareholders Equity $204.1M $170.2M
YoY Change 19.93% 15.27%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$34.21M -$13.63M
YoY Change 150.92% 2.1%
Depreciation, Depletion And Amortization $160.0K $180.0K
YoY Change -11.11% -10.0%
Cash From Operating Activities -$24.43M -$10.50M
YoY Change 132.67% 17.06%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.360M -100.0K
YoY Change 2260.0% -200.0%
NET CHANGE
Cash From Operating Activities -24.43M -10.50M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -2.360M -100.0K
Net Change In Cash -26.79M -10.60M
YoY Change 152.74% 19.5%
FREE CASH FLOW
Cash From Operating Activities -$24.43M -$10.50M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$24.43M -$10.50M
YoY Change 132.67% 17.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2315000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4025000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7360000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1644000
CY2018Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
17750000
CY2018Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1056000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
17192000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52643000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45241000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
96561000
CY2018Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12846000
CY2017Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11401000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
86064000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32306000
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1773000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58305000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
293662000
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
270725000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
289458000
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
293662000
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
270725000
CY2018Q1 amrn Stockholders Equity Adjusted Balance
StockholdersEquityAdjustedBalance
-65318000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
70007000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
423000
us-gaap Profit Loss
ProfitLoss
-58305000
us-gaap Profit Loss
ProfitLoss
-34575000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
11000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
38000
us-gaap Share Based Compensation
ShareBasedCompensation
7381000
us-gaap Share Based Compensation
ShareBasedCompensation
6976000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1140000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1147000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
323000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
323000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4991000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17490000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9833000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4307000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-577000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4907000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-568000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-58000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-3828000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-248000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-336000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
24146000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
21709000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5614000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74237000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2437000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62863000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11645000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28620000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12787000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
448000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34243000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24420000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
amrn Proceeds From Issuance Of Exchangeable Debt
ProceedsFromIssuanceOfExchangeableDebt
30000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1207000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70007000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
423000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1826000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
396000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
15107000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6713000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2680000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
98851000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
102857000
us-gaap Interest Paid Net
InterestPaidNet
10251000
us-gaap Interest Paid Net
InterestPaidNet
7546000
us-gaap Income Taxes Paid
IncomeTaxesPaid
805000
us-gaap Income Taxes Paid
IncomeTaxesPaid
778000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting estimates are based on historical experience and other factors that are considered reasonable under the circumstances. Estimates are used in determining such items as provisions for sales returns, rebates and incentives, chargebacks, and other sales allowances; depreciable/amortizable lives; asset impairments; valuation allowance on deferred taxes; probabilities of achievement of performance conditions for certain equity awards; amounts recorded for licensing revenue; contingencies and accruals; and valuations of derivative and long-term debt instruments. Because of the uncertainties inherent in such estimates, actual results may differ from these estimates. Management periodically evaluates estimates used in the preparation of the condensed consolidated financial statements for continued reasonableness.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Concentration of Credit Risk</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains substantially all of its cash and cash equivalents in financial institutions believed to be of high-credit quality.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A significant portion of the Company&#8217;s sales are to wholesalers in the pharmaceutical industry. The Company monitors the creditworthiness of customers to whom it grants credit terms and has not experienced any credit losses. The Company does not require collateral or any other security to support credit sales. Three customers individually accounted for 10% or more of the Company&#8217;s gross product sales. Customers A, B, and C accounted for 27%, 31%, and 31%, respectively,&#160;of gross product sales for the six months ended June&#160;30, 2018, and represented 33%, 37%, and 22%, respectively, of the gross accounts receivable balance as of June&#160;30, 2018. Customers A, B, and C accounted for 30%, 27%, and 35%, respectively, of gross product sales for the six months ended June&#160;30, 2017 and represented 37%, 24%, and 25%, respectively, of the gross accounts receivable balance as of June&#160;30, 2017. The Company has not experienced any significant write-offs of its accounts receivable.</p></div>
amrn Number Of Patients Enrolled And Randomized In Study
NumberOfPatientsEnrolledAndRandomizedInStudy
8175
amrn Number Of Sales Professionals
NumberOfSalesProfessionals
170
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
92403000
amrn Accounts Receivable Credit Period
AccountsReceivableCreditPeriod
P30D
CY2018Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
67004000
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
57802000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018Q2 amrn Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-34210000
CY2017Q2 amrn Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-13634000
amrn Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-58305000
amrn Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-34575000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
293662000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
270725000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
289458000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2018Q2 amrn Long Term Debt Current Net Of Accrued Interest
LongTermDebtCurrentNetOfAccruedInterest
27154000
CY2017Q4 amrn Long Term Debt Current Net Of Accrued Interest
LongTermDebtCurrentNetOfAccruedInterest
21569000
CY2018Q2 us-gaap Long Term Debt
LongTermDebt
86718000
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P12Y1M6D
CY2018Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11624000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11624000
CY2018Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3821000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3498000
CY2018Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
10107000
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
7044000
CY2018Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
10810000
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
10844000
CY2018Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
19592000
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
12372000
CY2018Q2 us-gaap Inventory Gross
InventoryGross
40509000
CY2017Q4 us-gaap Inventory Gross
InventoryGross
30260000
CY2018Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
416000
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2015Q1 amrn Private Placement Closing Date
PrivatePlacementClosingDate
2015-03-30
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52800000
CY2015Q1 amrn Equity Offering Costs
EquityOfferingCosts
700000
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.50
CY2015Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
0.1
CY2015Q1 us-gaap Share Price
SharePrice
2.39
CY2015Q2 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
31300000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
25281555
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
956232
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
221345
CY2018Q2 amrn Cash Discount Percent
CashDiscountPercent
0.02
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
48093000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
106853000
amrn Provision Related To Prior Period Sales
ProvisionRelatedToPriorPeriodSales
1305000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
56177000
amrn Credits Payments Made For Prior Period Sales
CreditsPaymentsMadeForPriorPeriodSales
34647000
CY2018Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
62817000
CY2017Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
19054000
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
27198000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
76790000
amrn Provision Related To Prior Period Sales
ProvisionRelatedToPriorPeriodSales
1221000
amrn Credits Payments Made For Prior Period Sales
CreditsPaymentsMadeForPriorPeriodSales
21623000
CY2017Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
35934000
us-gaap Revenue Practical Expedient Financing Component
RevenuePracticalExpedientFinancingComponent
true
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
45210000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
248000
CY2018Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
18806000

Files In Submission

Name View Source Status
0001564590-18-018242-index-headers.html Edgar Link pending
0001564590-18-018242-index.html Edgar Link pending
0001564590-18-018242.txt Edgar Link pending
0001564590-18-018242-xbrl.zip Edgar Link pending
amrn-10q_20180630.htm Edgar Link pending
amrn-20180630.xml Edgar Link completed
amrn-20180630.xsd Edgar Link pending
amrn-20180630_cal.xml Edgar Link unprocessable
amrn-20180630_def.xml Edgar Link unprocessable
amrn-20180630_lab.xml Edgar Link unprocessable
amrn-20180630_pre.xml Edgar Link unprocessable
amrn-ex311_6.htm Edgar Link pending
amrn-ex312_10.htm Edgar Link pending
amrn-ex321_11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending